TY - JOUR
T1 - Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation–a single-center experience
AU - Shargian-Alon, Liat
AU - Yahav, Dafna
AU - Rozovski, Uri
AU - Dovrat, Sara
AU - Amitai, Irina
AU - Sela-Navon, Michal
AU - Pasvolsky, Oren
AU - Raanani, Pia
AU - Yeshurun, Moshe
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/7/29
Y1 - 2019/7/29
N2 - Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4–11) vs. 9.6 (range, 3.2–30) mg/dL, respectively, p =.004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1–2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.
AB - Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4–11) vs. 9.6 (range, 3.2–30) mg/dL, respectively, p =.004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1–2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.
KW - Autologous
KW - HHV-6
KW - human herpes virus 6
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=85072711858&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1576869
DO - 10.1080/10428194.2019.1576869
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30773083
AN - SCOPUS:85072711858
SN - 1042-8194
VL - 60
SP - 2230
EP - 2236
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -